NCT04718740View on ClinicalTrials.gov

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

October 26, 2022

Study Completion Date

July 15, 2023

Conditions
Recurrent Ovarian Cancer
Interventions
DRUG

fluzoparib

Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib

Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY